Long non-coding RNAs in colorectal cancer

Xia Xie¹, Bo Tang¹, Yu-Feng Xiao¹, Rui Xie¹, Bo-Sheng Li¹, Hui Dong¹,², Jian-Yun Zhou¹ and Shi-Ming Yang¹

¹ Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing, P.R. China
² Division of Gastroenterology, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California, USA

Correspondence to: Shi-Ming Yang, email: shimingyang@yahoo.com
Correspondence to: Jian-Yun Zhou, email: 13452166569@126.com

Keywords: colorectal cancer, long non-coding RNAs, epigenetic modifications, pseudogenes, X-inactive-specific transcript

Received: August 15, 2015  Accepted: November 21, 2015  Published: December 02, 2015

ABSTRACT

Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Despite substantial progress in understanding the molecular mechanisms and treatment of CRC in recent years, the overall survival rate of CRC patients has not improved dramatically. The development of CRC is multifactor and multistep processes, in which abnormal gene expression may play an important role. With the advance of human tumor molecular biology, a series of studies have highlighted the role of long non-coding RNAs (lncRNAs) in the development of CRC. CRC-related lncRNAs have been demonstrated to regulate the genes by various mechanisms, including epigenetic modifications, lncRNA-miRNA and lncRNA-protein interactions, and by their actions as miRNA precursors or pseudogenes. Since some lncRNAs can be detected in human body fluid and have good specificity and accessibility, they have been suggested to be used as novel potential biomarkers for CRC diagnosis and prognosis as well as in the prediction of the response to therapy. Therefore, in this review, we will focus on lncRNAs in CRC development, the mechanisms and biomarkers of lncRNAs in CRC.

INTRODUCTION

In developed countries, nearly 100 million people suffer from CRC each year, and the mortality rate approaches 33% [1]. Almost 50% of patients exhibit recurrence and die within 5 years, even when there is a curative intent for diagnosis or treatment [2]. Therefore, there is an urgent need to improve the early diagnosis and treatment of CRC. The genesis of CRC involves multi-factorial and complex steps in which abnormal gene expression plays an important role [3]. Intensive investigations over the last few decades have focused on the role of protein-coding genes in the pathogenesis of CRC. However, although only 1% of the human genome encodes proteins, 70% to 90% of the genome can be transcribed at some point during development to produce a large transcriptome of non-coding RNAs (ncRNA), 4-9% of which is transcribed to yield many short or long RNAs with limited protein-coding capacity [4]. Of these, the transcribed RNA molecules that are longer than 200 nucleotides and lack an open reading frame are defined as the lncRNAs [5]. LncRNAs are non-protein coding transcripts that are implicated in a number of important events, such as epigenetic, transcriptional, and post-transcriptional regulation [6]. LncRNAs exhibit unique profiles in various human cancers, reflecting disease progression and serving as a predictor of patient outcomes [7].

Many studies have reported that lncRNAs participate in various aspects of cell biology and potentially contribute to tumor development. Recently, the roles of lncRNAs as drivers of tumor suppressors and oncogenic function have been examined in diverse cancer types [8]. Over the past decades, multiple studies have shown that the CRC-related lncRNAs closely correlate with diverse biological processes involved in CRC progression through stimulating or inhibiting cell proliferation, apoptosis, differentiation, invasion and metastasis (Table1). The lncRNAs are widely involved in the gene expression network at various
levels, including chromatin modification, transcription, and posttranscriptional processing [9]. For example, the lncRNAs Xist (X inactive-specific transcript) and HOTAIR (HOX Antisense Intergenic RNA) interact with chromatin remodeling complexes to induce local or global changes in chromatin packaging, leading to reduced target gene expression [10, 11]. LncRNAs can act as “miRNA sponges” and sequester miRNAs to inactivate these small regulatory RNAs and then to decrease the expression of miRNA target genes [12]. LncRNAs can also act as co-activators of transcription factors by interacting with RNA binding proteins and the interaction finally alters the localization and activity of the proteins [13]. Currently, the functions of lncRNAs remain poorly understood compared to those of short ncRNAs. Some lncRNAs have been detected in human body fluids by PCR, such as in plasma and urine [14, 15]. Here we will review the functions, mechanisms and biomarkers of CRC-associated lncRNAs from recently published papers, particularly focusing on the latest insights regarding progression of CRC.

### Table 1: The common abnormal expression of LncRNAs in CRC

| LncRNA   | Loci       | Length  | Biological Function                                                                                                                                 |
|----------|------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| CCAT1    | 8q24.21    | 2628nt  | Up-regulating c-Myc, promoting tumor cell proliferation and migration, function as a oncogene [61, 86]                                                  |
| CCAT2    | 8q24.21    | 340nt   | Up-regulating c-Myc, promoting tumor cell proliferation a and migration, function as a oncogene [64, 87]                                                |
| CCAT1-L  | 8q24.21    | 5200nt  | Up-regulating c-Myc, promoting tumor cell proliferation and migration, function as a oncogene [63]                                                   |
| H19      | 11q15.5    | 6295nt  | A dual function of oncogene and tumor suppressor gene [38, 41, 54, 88]                                                                              |
| HOTAIR   | 12q13.13   | 2337nt  | Recruiting PCR2 and LSD1 complexes to HOXD, silence HOXD, function as a oncogene [30, 89, 90]                                                       |
| MALAT1   | 11q13.1    | 8708nt  | Regulating alternative splicing of the endogenous target gene, promoting cell proliferation, migration, and invasion function as a oncogene [15, 67, 69] |
| MEG3     | 14q32.2    | 1.6–1.8kb | Promoting the expression of P53 gene, inhibiting tumor growth, function as a tumor suppressor gene [42, 45, 91]                                       |
| OCC-1    | 12q23.3    | 1139nt  | Promoting cell proliferation, function as a oncogene [32]                                                                                         |
| PTENP1   | 9P21       | 3917nt  | Binding to the regulatory region of miRNAs and the tumor suppressor gene-PTEN, function as a tumor suppressor gene [56]                            |
| UCA1     | 19P13.12   | 1441nt  | Affecting cell growth and development, promoting tumor invasion, function as a oncogene [92, 93]                                                  |
| HULC     | 6p24.3     | 500nt   | Regulating cell invasion and metastasis through competitively binding to miRNA, function as a oncogene [49]                                         |
| Loc285194| 3q13.31    | 2105nt  | Regulating the expression of P53 and miRNA, inhibiting tumor growth, function as a tumor suppressor gene [29]                                    |
| PCAT1    | 8q24       | 725nt   | Promoting cell proliferation through association with PRC2, function as a oncogene [46, 47]                                                       |
| E2F4     | 16q21-22   | ~5000nt | Avoiding excessive cell proliferation [94]                                                                                                         |
| CRNDE    | 16q12.2    | *       | Promoting cell proliferation, migration and invasion of colorectal tumor cells by acting as ceRNAs or interacting with chromatin-modifying complexes to regulate gene expression via epigenetic changes, function as a oncogene [83, 95-97] |

*: Related Content inaccurate; OCC-1: overexpression in colon carcinoma-1; UCA1: urothelial cancer-associated 1 CRNDE: Colorectal neoplasia differentially expressed.
information could be helpful to better understand the mechanisms and functions of CRC-related lncRNAs.

What are the lncRNAs

LncRNAs are RNA polymerase II (RNAPII) transcripts that can’t encode for proteins [16, 17]. In the 1980s and 1990s, some lncRNAs were first identified, such as X-inactive specific transcript (XIST) and H19 were discovered by searching cDNA libraries for clones of interest [18, 19]. The size cut-off distinguished lncRNAs from small ncRNAs, such as microRNAs, small nucleolar RNAs (snoRNAs) and small interfering RNAs (siRNAs). There are a variety of different evolutionary scenarios for the emergence of functional lncRNAs, and they are roughly classified into five types (Figure 1): A) a protein-coding gene acquires structure interruption and is transformed into a lncRNA; B) through chromatin reorganization, two un-transcribed regions and another independent sequence region are juxtaposed and produce multiple exons of lncRNA; C) duplication of a non-coding gene by retrotransposition generates either a functional non-coding retrogene or a nonfunctional non-coding retropseudogene; D) the adjacent repeats of non-coding RNA originate in two tandem duplication events; and E) insertion of a transposase gene gives rise to a functional lncRNA [4]. Recent studies on lncRNAs in different species revealed that the size and function of various populations of RNA molecules differ. These lncRNAs include not only antisense, intronic, and intergenic transcripts but also pseudogenes and retrotransposons. According to the genetic view, these lncRNAs are in many forms: they can be very small or several hundred kilobases long; they may be spliced or unspliced; they

Figure 1: The origins of lncRNAs. The possible origins of lncRNAs are divided into five broad categories: A. A protein-coding gene acquires structure interruption and is transformed into a lncRNA; B. As a result of chromatin reorganization, two untranscribed regions and another independent sequence region are juxtaposed and produce multiple exons of lncRNA; C. The duplication process of a non-coding gene by retrotransposition generates either a functional non-coding retrogene or a nonfunctional non-coding retropseudogene; D. Adjacent repeats of non-coding RNA originate from two tandem duplication events; and E. The insertion of a transposase gene gives rise to a functional lncRNA.
can form linear or tertiary structures; they may have a poly-A tail; and they may interact with DNA, proteins, or other RNA molecules [20]. lncRNAs generally fall into five broad categories: (1) sense, when overlapping one or more exons of another transcript on the same strand; (2) antisense, when overlapping one or more exons of another transcript on the opposite strand; (3) bidirectional, when its expression and that of a neighboring coding transcript on the opposite strand are initiated in close genomic proximity; (4) intronic, when it is derived from an intron of a second transcript; and (5) intergenic, when it lies as an independent unit within the genomic interval between two genes [4]. This information on their positions will help scientists estimate the features of IncRNA. IncRNAs may be located in the nuclear, chromatin, or cytoplasmic fractions of cells. The different localizations of IncRNAs suggest different biological functions. Increasing evidence indicates that IncRNAs may function as signals for transcription and decoys to transcription factors so that chromatin-modifying enzymes can be recruited to target genes and scaffolds to bring together multiple proteins to form ribonucleoprotein complexes [5, 21]. An additional biological function may include serving as a “sponge” to microRNAs [22]. Until now, the human genome and transcriptome sequencing databases demonstrated that half of the human genome is IncRNA. Despite their abundance, few IncRNAs have been studied and even fewer have been functionally characterized. This is in contrast to the small ncRNAs, such as siRNAs, miRNAs, and piRNAs, which are highly conserved and involved in translational and post-transcriptional gene silencing through specific base pairing with their targets. While the numbers of characterized IncRNAs are increased, it is getting clear for their roles in stimulating or suppressing gene expression during cell differentiation and the development of human diseases [23, 24]. IncRNAs participate in epigenetic silencing, gene transcription and translation, the cell cycle and the apoptosis regulation process that is involved in DNA methylation, genomic imprinting, histone modification, microRNA interaction, protein interaction, and chromosomal instability [9, 25, 26]. Nevertheless, the biological functions of IncRNAs in the cancer cells are not well understood. To date, growing evidence suggests that cancer-associated IncRNAs, similar to protein-coding genes, may mediate oncogenic or tumor suppressing effects, and they may be a new class of cancer therapeutic markers [27, 28].

**LncRNAs in CRC development**

To date, an increasing number of studies have shown abnormal expression of IncRNAs may inhibit tumor suppressor genes or cancer-promoting genes in the development of CRC. For example, loc285194 acts as a tumor suppressor but HOTAIR is the first identified IncRNA that plays a critical oncogenic role through epigenetic regulatory mechanisms [29, 30]. Gibb EA et al conjectured that abnormal expression of IncRNA was generally present in tumors [31]. Furthermore, recent studies have found different and unique expression of IncRNAs in CRC, and therefore IncRNAs could be new molecular markers in tumor diagnosis and treatment [32]. A few IncRNAs identified recently to be involved in the pathogenesis of CRC are showed in Table 1. Here, we will describe the status of several common CRC-associated IncRNAs according to their mechanisms in CRC.

**Epigenetic transcriptional regulatory IncRNAs**

A general model for IncRNA-dependent gene-silencing mechanism is that IncRNAs first interact with chromatin to recruit histone-modifying enzymes, then induce chromatin modification and DNA methylation, and finally contribute to the epigenetic silencing of target genes. In this section, we will illustrate some epigenetic transcriptional regulatory CRC-associated IncRNAs.

**HOTAIR**

HOX transcript antisense RNA (HOTAIR) can directly stimulate chromatin modifications related to tumor invasiveness and metastasis. HOTAIR plays a critical role in carcinogenesis through epigenetic regulatory mechanism, which was identified from a custom tilling array of the HOXC locus (12q13.13; ref. 2). HOTAIR is located in the 12q13.13 region, and its full length is 2.3 kb. It can form multiple double stem-loop structures to bind to the lysine-specific demethylase 1 (LSD1) and polycomb repressive complex 2 (PRC2) to form histone modification complexes [30], which stimulate the two complexes’ integration with the corresponding specificity genomic loci and cause H3K27me3 (histone H3 tri-methylated at lysine 27) and H3K4me2 (histone H3 dimethyl Lys4) methylation, leading to HOXD silencing [33, 34]. In addition, Kaijiang Zhang et.al found that HOTAIR also might accelerate cell cycle progression through EZH2 (predominant PRC2 complex component) but not LSD1 [35]. Clinical research showed that the expression levels of HOTAIR and the prognosis of patients are positively correlated in CRC, indicating that HOTAIR promotes metastasis, recurrence and prognosis of CRC [30, 36]. These findings suggest that HOTAIR plays an active role in modulating the cancer epigenome and may be an important target for the diagnosis and therapy of CRC.

**H19**

H19, located on chromosome 11p15.5, close to the IGF II gene locus, is a maternally imprinted gene. It contains five exons and four introns with a length of 2.3 kb. The H19 gene does not encode protein but encodes a capped, spliced and polyadenylated 2.7 kb RNA. The imprinting of H19 is controlled by a region located 4 kb upstream of H19, which is defined as the H19 differentially
maternal methylated region (DMR) or imprinting control region (ICR). The H19 locus is subject to genomic imprinting and has often been used as a model for the study of epigenetic regulation [37, 38]. The oncogenic function of H19/miR-675 is to down-regulate tumor suppressor retinoblastoma (RB) in human CRC cells. Moreover, the proto-oncogene transcription factor c-Myc directly activates H19 in CRC implying that H19 is directly involved in the activation of the downstream gene expression of c-Myc [39]. However, studies have also indicated that H19 is a tumor suppressor in vivo. After H19 gene is knocked out, the capacity for tumor growth, invasion and metastasis is enhanced in murine models of colon tumorigenesis [40]. Therefore, abnormal expression of the H19 gene is related to the generation of CRC, and it dually functions as an oncogene and tumor suppressor gene through a variety of mechanisms [41].

MEG3

Maternally expressed gene 3 (MEG3) is also an imprinted gene located at 14q32 that encodes an lncRNA. Multiple mechanisms contribute to the decreased expression of MEG3 in tumors, including gene deletion, promoter hypermethylation, and hypermethylation of the intergenic differentially methylated region. Furthermore, the treatment of human cancer cell lines with a methylation inhibitor results in MEG3 expression. The promoter region of MEG3 is rich in CpG dinucleotides. The methylation pattern of the 2.1 kb 5’-flanking region of MEG3 contains a total of 112 CpG dinucleotides upstream of the first exon, which is arbitrarily divided into four regions. Regions 1 and 4 contain functionally important sequences for gene expression [42]. The loss of MEG3 expression, its deletion from genomic DNA and the degree of promoter methylation are associated with aggressive tumor growth. These findings indicate that MEG3 may play a significant role as a novel long non-coding RNA tumor suppressor [43, 44]. Experimental data demonstrate that p53 is a target of MEG3 and that transfection of MEG3 induces a significant increase in p53 protein levels in human cancer cell lines [45].

PCAT-1

The lncRNA prostate cancer-associated ncRNA transcript 1 (PCAT-1) is located in the chromosome 8q24 gene desert approximately 725 kb upstream of the c-MYC oncogene, and is involved in the progression of human prostate cancer. It has been shown that PCAT-1 is up-regulated in prostate tumor tissues and promotes prostate cancer cell proliferation via PRC2 [46]. Interestingly, unlike HOTAIR, PCAT-1 is repressed by PRC2. PCAT-1 functions chiefly as a transcriptional repressor by promoting the trans-regulation of genes preferentially involved in mitosis and cell division. PCAT-1 expression in CRC tissues is also significantly up-regulated compared with the matched normal tissues. There is a positive correlation between PCAT-1 expression and distant metastasis of CRC. The overall survival rate of the patients with high expression of PCAT-1 is significantly lower than those with low expression. In addition, multivariable Cox regression analysis identified PCAT-1 over-expression as an independent prognostic factor for CRC [47]. The molecular mechanisms underlying the altered expression of PCAT-1 in CRC remain unclear although it has been reported to be regulated by the PRC2 complex in prostate cancer cells.

CCAT2

Studies showed that CCAT2 participates in epigenetic transcription by inducing chromosomal instability (CIN). CCAT2 is highly overexpressed in microsatellite-stable CRC and promotes tumor growth and metastasis. Studies have demonstrated CCAT2’s ability to underlie CIN, manifested by the loss or gain of large portions or whole chromosomes, eventually resulting in aneuploidy, a characteristic trait of MSS CRCs. This is likely to occur through CCAT2’s effects on downstream mediators, such as MYC and/or other WNT target genes. The direct correlation between MYC and MIR17HG in CIN has been previously demonstrated in that a transient excess of MYC activity could elicit genomic instability and carcinogenesis [48].

LncRNA-RNA interactional lncRNAs

Recent work has highlighted a novel role for interactions between lncRNAs and RNA sequences. LncRNAs can function as competing endogenous RNAs (ceRNAs) to sponge miRNAs or as pseudogenes to serve as decoys for miRNAs, resulting in changes of target genes and the biological function of the miRNAs.

HULC

Highly Up-regulated in Liver Cancer (HULC) is a typical example of “miRNA sponge”, which is located on the human chromosome 6p24.3 and consists of two exons. The length of its single intron is 500 bp. HULC is up-regulated in hepatocellular carcinoma (HCC) [49], but it is over-expressed not only in HCC but also in CRC that has metastasized to the liver. HULC is up-regulated in hepatic CRC metastasis, which is relevant to its null expression in normal tissues, primary CRC, or those cancers that metastasize to lymph nodes [50]. It contains a polyA tail and a particularly conserved miR-372 target site [49]. HULC binds to miR-372 and acts as a sponge to competitively inhibit miRNA from binding to a sense mRNA transcript. Since a recent study suggests that HULC may be involved in the process of CRC cell metastasis to the liver, it may become a new marker for evaluating the metastasis of CRC to the liver.
Loc285194

Loc285194, also called LSAMP antisense RNA 3, is an lncRNA of more than 2 kb in length that consists of 4 exons located at osteo3p13.31. Loc285194 functions as a potential tumor suppressor. Study showed that loc285194 is a direct transcriptional target of p53 with two binding sites of miR-211 in its exon 4. Loc285194 is also consistently down-regulated in colon tumor specimens compared with normal specimens and is a direct target of p53 through the negative regulation of miR-211 [29].

H19

LncRNA is not only used as a model for the study of particular epigenetic regulation but also functions as miRNA sponges and as a miRNA precursor in CRC. For example, H19 can promote EMT progression and accelerate tumor growth by acting as competing endogenous RNA (ceRNA) for miR-138 and miR-200a in CRC [51]. Furthermore, H19 may form the precursor of miR-675 by an intracellular shearing action [52]. H19 expression is positively correlated with the level of miR-675, and miR-675 down-regulates RB expression [53]. The 3’-UTR of RB mRNA aligns with the sequence of mature miR-675, and the level of RB protein also appears to be negatively correlated with the levels of both H19 and miR-675 in human colon cancer cells [54]. These findings indicate that H19 can influence CRC progress through functioning as ceRNA or acts as precursor of miRNA, thus it can serve as a potential target for CRC treatment.

PTENP1

The 3’UTR of PTENP1 is a pseudogene of PTEN. It can compete with PTEN for miRNA binding sites by binding to the regulatory region of miRNAs and can also be translated into the tumor suppressor protein PTEN. These findings suggest that the pseudogene participates in the regulation of homologous genes through non-coding RNA [55-57]. The proposed mechanisms remain controversial, and further investigation is required.

LncRNA-protein interactional lncRNAs

It has been reported that many CRC-associated lncRNAs can directly bind to the target proteins or indirectly decrease or increase the expression levels of the target genes.

CCAT

Colon cancer-associated transcript (CCAT) family members and some novel lncRNA transcripts map to the highly conserved 8q24.21 region that encompasses rs6983267. This region of interest has been shown to interact with MYC and the SNP rs6983267 at position 128.4 Mb, which influences MYC transcription [58-60]. It contains CCAT1 (Colorectal Cancer Associated Transcript 1), CCAT1-L (CCAT1, the Long isoform) and CCAT2 (Colorectal Cancer Associated Transcript 2). They participate in cell growth, cell cycle invasion and metastasis that is correlated to the nuclear transcription factor c-MYC.

CCAT1

CCAT1 is 2628 nt in length with two exons corresponding to nucleotides 1-288 and 289-2612. The gene has an unusually long intron (approximately 9 kb). Its expression is tightly correlated with c-MYC [60]. Concretely, c-Myc directly binds to the E-box element in the promoter region of CCAT1 to regulate both the promoter activity and expression of CCAT1. CCAT1 is up-regulated in the majority of primary CRC tumors, precancerous polyps (adenomas), tumor-proximal colonic epithelia, lymph nodes, blood, and distant CRC metastases, but not in normal tissues [61]. Alaiyan B found that CCAT1 was up-regulated in both pre-malignant conditions and all disease stages in CRC [62]. Therefore, these novel biomarkers can be used for CRC screening, diagnosis, staging and novel therapies.

CCAT1-L

CCAT-L is transcribed from 8q24.21, and its full length is 5200 nt. Specifically, it is transcribed in human CRC from a locus 515 kb upstream of MYC. CCAT-L located in the cell nucleus contains two exons and is polyadenylated. The over-expression of CCAT1-L can promote CRC tumorigenesis through the transcriptional regulation of MYC and the promotion of long-range chromatin looping. CCAT1-L localizes to its site of transcription and functions in the maintenance of long-range interactions between the MYC promoter. CCAT1-L interacts with CTCF and modulates it to bind to chromatin at the MYC locus [63]. These results revealed a novel relationship between the chromatin organization regulated by lncRNA and MYC expression in colon cancer.

CCAT2

CCAT2, a 340-nt ncRNA, is transcribed from the MYC-335 region. CCAT2 expression is significantly higher in the CRC tissue than the adjacent mucosa. Moreover, microsatellite-stable (MSS) cancers have higher CCAT2 expression than microsatellite-unstable (MSI-H) tumors and the adjacent normal colon mucosa. CCAT2 enhances invasion and metastasis by influencing the MYC-activated miRNAs (miR-17-5p and miR-20) and the general activation of WNT signaling [64, 65]. Hui Ling et al. used RNA immunoprecipitation analysis to examine the physical interaction between CCAT2 and TCF7L2 by pulling down the RNAs that colocalized with TCF7L2 protein, and they found that endogenous CCAT2 could bind to TCF7L2 protein, increasing MYC expression in colon cancer cells [64].
MEG3

The lncRNA MEG3 not only participates in methylation but also can influence the expression of the transcription factor p53. One study showed that p53 is a target gene of MEG3 and overexpression of MEG3 leads to a significant increase in p53 protein levels in human cancer cell lines [45]. The study also found that MEG3 is absent from the human colon cancer cell lines HT29 and HT116, and an MEG3 isoform can cause a significant enhancement of p53-mediated reporter expression in HCT116 colon cancer cells [66].

MALAT-1

Human cancer metastasis is associated with lung adenocarcinoma transcript 1 (MALAT-1), a long non-coding RNA that consists of more than 8,000 nt and is located on chromosome 11q13. It is highly expressed in many cancers and greatly related to metastasis. High expression of MALAT-1 is a strong predictor of poor prognosis in early cancers; however, some patients with low MALAT-1 levels also die during the 5-year follow-up period. MALAT-1 promotes cell migration, invasion, and metastasis [67]. Studies have found that a particular sequence (fragment 6918 nt-8441 nt), located at the 3’ end of MALAT-1 is correlated with several biological processes: cell proliferation, migration, and invasion of human colorectal malignant neoplasms. Therefore, this motif at the 3’ end of the MALAT-1 gene may be an important functional motif of MALAT-1. MALAT-1 is over-expressed in 50-80% of colon cancers, but exhibits low expression or no expression in normal tissues according to in situ hybridization [68]. MALAT-1 also accelerates CRC development and metastasis [69]. MALAT-1 is involved in mRNA splicing and nuclear paraspeckle function in cancer, and contributes to gene expression by regulating mRNA splicing, editing, and export [70]. Using CHIP combined with gene chip technology, Koshimizu TA and his colleagues found that there were transcription factor CREB binding sites in the MALAT-1 promoter region in neuroblastoma cell lines [71]. Therefore, MALAT-1 is a potential drug target and may facilitate the early diagnosis and establishment of a prognosis for neuroblastoma.

The regulatory mechanisms of lncRNAs in CRC

lncRNAs are nearly involved in the whole life cycle of genes, from transcription to RNA splicing, degradation and translation. lncRNAs regulate gene expression in a variety of ways and have diverse mechanisms for regulating gene expression. lncRNAs have different regulatory mechanisms: they can act not only as the major transcription factor but also as one of the co-regulatory factors (co-regulators). Recent studies have demonstrated that lncRNAs are widely involved in the regulation of the gene expression network at epigenetic, transcriptional and post-transcriptional levels. The mechanism involved is closely associated with the genesis of CRC. Previous studies on lncRNAs have discovered that lncRNAs can activate or inhibit the expression of genes in a variety of dimensions, and the regulatory mechanisms are being uncovered. Now, we will focus on the mechanisms of its involving the development of CRC (Figure 2).

Epigenetic modifications

lncRNAs play an important role in the epigenetic modifications of genes [72]. First, lncRNAs interact with a variety of chromatin modification enzymes, and then induce chromatin modification and DNA methylation. Eventually, they contribute to the epigenetic silencing or activation of target genes [73]. lncRNAs participate in allele silencing and the maintenance of epigenetic modifications during embryonic development. The targeting of epigenetic modifiers (EMs) by lncRNAs provides a much sought-after model to explain how EMs gains locus specificity and has since been suggested as a general mechanism for trans-acting lncRNAs [9, 74]. The major epigenetic modifications of CRC include DNA methylation, histone modifications, chromosomal modification (Figure 2a). The X-inactivation center (Xic) now serves as a typical model for understanding epigenetic transcriptional regulation by lncRNA. The typical example is X inactivation by the X-inactive-specific transcript (XIST/Xist) in mammals. Xist RNA directly binds to polycomb repressive complex 2 (PRC2), which is the epigenetic complex responsible for the trimethylation of histone H3 at Lys27 (H3K27me3), and targets PRC2 to Xi, silencing the whole chromosome [74]. Indeed, like Xist, the lncRNA HOTAIR also can bind to the PRC2, interact with chromatin remodeling complexes to induce heterochromatin formation in specific genomic loci, leading to reduced target gene expression [30, 36]. Those lncRNAs achieve their repressive function by coupling with histone modifying or chromatin remodeling protein complexes.

However, H19, which does not directly bind to PRC2 protein, is an imprinted and maternally expressed lncRNA that is spliced, polyadenylated, and exported into the cytoplasm where it accumulates to very high levels [19]. MEG3 is found to be abnormal CpG methylation in CRC, in which its expression is decreased. The hypermethylation in the MEG3 promoter region as well as the intergenic germ line-derived differentially methylated region (IG-DMR) would cause proliferation of cancer cells and blood vessels and then accelerate tumor metastasis and malignant [75]. CIN is another mode of epigenetic modification, which could be the underlying mechanism for CCAT-2 promoted CRC growth and metastasis. CCAT-2 may have effects on downstream mediators such as MYC and/or other WNT target genes [64]. Therefore,
lncRNAs may be regulators of epigenetic mechanisms while actively participating in gene regulation. Despite of these exciting findings, the basic mechanisms how these lncRNAs work are still unknown.

**LncRNA-miRNA interaction**

LncRNA can function as ceRNAs and “miRNA sponges” to antagonize their functions and lead to the de-repression of their endogenous targets, thereby imposing an additional level of post-transcriptional regulation. This LncRNA-miRNA interaction was first proposed in 2007 in a study that found the lncRNA IPS1 bound to the miRNA miR-399 and inhibited its ability to regulate PHO2 mRNA [76]. Recent evidence suggests that several CRC-related lncRNAs may also regulate gene expression by binding to miRNAs and consequently preventing specific miRNAs from binding to their target mRNAs (Figure 2b). This model more broadly suggests that lncRNAs, as well as other protein-coding mRNAs, may function as molecular “sponges” that binds miRNAs in order to indirectly control gene expression. A typical example of “miRNA sponges” is HULC, which is over-expressed in colorectal carcinomas that could metastasize to the liver [50]. HULC binds to miR-372 and acts as a sponge to competitively inhibit miRNA from binding to sense mRNA transcript. Recently, researchers developed different databases to facilitate the study of lncRNA-miRNA interactions, such as miRcode (http://www.mircode.org), DIANA-LncBase (http://www.mircomca.gr/LncBase) and CHIPBase (http://deepbase.sysu.edu.cn/chipbase/) [77-79]. This will contribute to a better understanding of lncRNAs and miRNAs.

**Figure 2: The regulatory mechanisms of lncRNAs in colorectal cancer.** LncRNAs regulate the proliferation, apoptosis, differentiation, invasion and metastasis of CRC in a variety of ways. A. LncRNAs induce chromatin modification, DNA methylation and histone acetylation and contribute to the epigenetic silencing or activation of target genes; B. LncRNAs regulate gene expression by binding to miRNAs and consequently preventing specific miRNAs from binding to their target mRNAs, thus regulating the expression of target mRNAs; C. LncRNAs act as pseudogenes or miRNA precursors; D. LncRNAs can serve as structural components or modulate protein activity or alter protein localization by binding to proteins.
LncRNA-protein interaction

LncRNAs can participate in global cellular behaviors by binding to specific proteins that contain nuclear transcription factors. Through LncRNA-protein interaction, LncRNAs can serve as structural components, modulating protein activity or altering protein localization (Figure 2d). As such, the mRNA stabilizing protein HuR accumulates in the cytoplasm when lncRNA-UFC1 is overexpressed, and the lncRNA-UFC1 binds directly to HuR, increasing the levels of β-catenin in HCC cells [80]. Guttman et al. studied 226 lncRNAs by RNA immunoprecipitation (RIP) analysis on the 28 types of chromatin complexes, and found that 12 kinds of complexes can bind to the studied LncRNAs. At least 30% (74/226) of LncRNAs can bind to one complex. However, LncRNA binding with multiple complexes is a widespread phenomenon [81]. In CRC, there are also many CRC-associated LncRNAs that directly bind to the target proteins or indirectly regulate the expression of the target genes. Indeed CCAT1-L, CCAT2, MEG3, Loc285194 and MALAT-1 promoter region have protein binding sites [29, 63, 64, 66, 71]. Taking CCAT2 as an example, Hui Ling et al. used RIP analysis to examine the physical interaction between CCAT2 and TCF7L2 by pulling down RNAs colocalized with TCF7L2 protein, and they found that endogenous CCAT2 could bind to TCF7L2 protein, and then up-regulated MYC expression in colon cancer cells [64]. Thus, one LncRNA is possibly binds to different proteins but the function may depend on its target protein.

As pseudogenes

Pseudogenes are always regarded as “outcasts” of functional genes. However in recent years, they have drawn increasing attentions. For example, the stability of mRNA is increased by pseudogenes which is transcribed by homologous genes through generating a shortened non-coding segments (Figure 2e). It is also found that pseudogene can influence the expression of homologous genes with transcribing antisense sequence. In CRC-associated LncRNA, the 3’UTR of PTENP1 is a tumor suppressor pseudogene, which can bind to the regulatory region of miRNAs but also bind to the tumor suppressor gene PTEN. Therefore, the 3’UTR of PTENP1 causes the decline of PTEN mRNA expression, and also can be translated into the tumor suppressor protein (PTEN). These findings suggest that the pseudogene participates in the regulation of homologous genes through non-coding RNA [55-57]. However, the underlying mechanisms remain controversial and the further investigation is required.

As precursor of miRNA

In addition to binding miRNA, several studies have demonstrated that LncRNAs can regulate gene expression by acting as miRNA precursors (Figure 2e). For example, H19 as the precursor of miR-675, can decrease the level of RB [52]. The 3’-UTR of RB mRNA aligned with the sequence of mature miR-675 and the level of RB protein also appears to be negatively correlated with the levels of both H19 and miR-675 in the human colon cancer cells [53]. This intriguing hypothesis indicates that H19 is derived from miR-675 to regulate CRC development.

Clinical biomarkers of LncRNAs in CRC

LncRNAs and their deregulation have been described across both solid and hematological malignancies. Similar to miRNAs, LncRNAs have both cell and tissue specificity and regulatory function. In most instances, evidence has relied on differences in transcript expression levels between disease- and non-disease-associated states. Ye Hu et al. used a LncRNA-mining approach, established a six-LncRNA signature. They demonstrated three dysregulated LncRNAs, AK123657, BX648207 and BX649059 were necessary for efficient invasion and proliferation suppression in CRC cell lines. This study provides an efficient classification tool for clinical prognosis evaluation of CRC [82]. Reliable molecular markers, analyzed in non-invasively obtained surrogate samples, may assist in the selection of the best possible diagnosis and treatment for individual cancer patients. These markers have various types, including diagnostic markers, prognostic markers, and therapeutic markers [28].

In recent years, there are few studies have investigated whether LncRNAs can serve as effective diagnostic and prognostic biomarkers for CRC. HOTAIR and CRNDE, for example, are upregulated in neoplastic tumor tissue and in the blood of CRC patients [83, 84]. Moreover, HOTAIR is associated with patients’ overall survival, and its high levels are correlated with TNM stage and histologic grade. These data suggest that HOTAIR levels in the blood may serve as potential surrogate prognostic marker in CRC [84]. With the development of experimental techniques, Kam Y. et al. applied CCAT1-specific peptide nucleic acid (PNA) based molecular beacons (TO-PNA-MB) to serve as a diagnostic probe for in situ (human colon biopsies) detection of CRC. In situ hybridization of selected TO-PNA-MB in human CRC specimens, CCAT1 expression was detected in all (4/4) subjects with pre-cancerous adenomas, and in all (8/8) patients with invasive adenocarcinoma tumors. These results suggest that CCAT1 TO-PNA-MB is a powerful diagnostic tool for the specific identification of CRC [85]. Another LncRNAs, CCAT2 may also be served as a
diagnostic biomarker since its expression is significantly higher in the tumor tissues as compared with the adjacent mucosae of 215 CRC and 94 paired non-neoplastic mucosal specimens obtained from patients from four different geographical regions [64]; Therefore, IncRNAs transcripts in the cancer tissues and in the plasma of patients are promising biomarkers for CRC.

CONCLUSIONS

Along with small RNAs and proteins, IncRNAs have broad applications in CRC diagnosis and treatment. The unique expression or over-expression of IncRNAs in CRC may be used to develop new tumor markers. However, since IncRNA research is still in its infancy, there are several unresolved issues using IncRNA as clinical biomarkers for the diagnosis and treatment of CRC. Furthermore, only a limited number of CRC-related IncRNAs has been well characterized. Therefore, a systematic identification of IncRNAs and a better understanding of their mechanisms are needed to facilitate their applications to the diagnosis and treatment of CRC. Recently, with a growing evidence for the role of tumor-specific IncRNA and the site-specific action of cis-acting IncRNAs in tumor development, researchers have begun to develop IncRNA-targeting drugs.

Although the molecular mechanisms of IncRNAs are not well understood, the IncRNAs summarized in Table 1 may provide a glimpse of the full range of IncRNA functions in cancer. Further studies are needed to focus on the mechanisms and regulation of IncRNAs in normal and cancer cells. With the development of research and technology, IncRNAs will facilitate the diagnosis and treatment of CRC in the near future.

Abbreviations

CRC, colorectal cancer; IncRNAs, long non-coding RNAs; XIST, X-inactive specific transcript; MALAT-1, metastasis associated lung adenocarcinoma transcript 1; HOTAIR, human homeobox transcript antisense RNA; PRC2, polycomb repressive complex 2; CCAT1, colorectal cancer associated transcript 1; CCAT2, colorectal cancer associated transcript 2; HULC, highly up-regulated in liver cancer; CIN, chromosomal instability; c-Myc, cellular homologue of avian myelocytomatosis virus oncogene; CREB, cAMP response element-binding protein; PCAT-1, Prostate Cancer Associated Transcripts 1; HER2, Human Epithelial Growth Factor Receptor 2; snoRNAs, small nucleolar RNAs; siRNAs, small interfering RNAs.

ACKNOWLEDGMENTS

This work was supported by grants from the National Natural Science Foundation of China (No. C81502422).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Ottaiano A, Franco R, Aiello TA, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di BA, Napolitano M, Ierano C, et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006; 12:2795-2803.
2. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lamsdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116:544-573.
3. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013; 108:2419-2425.
4. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136:629-641.
5. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43:904-914.
6. Zhang J, Zhang A, Wang Y, Liu N, You Y, Kang C, Pu P. New insights into the roles of ncRNA in the STAT3 pathway. Future Oncol 2012; 8:723-730.
7. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011; 21:354-361.
8. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1:391-407.
9. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 2012; 482:339-346.
10. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-1323.
11. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322:750-756.
12. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010; 38:5366-5383.
13. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK, Kurokawa R. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 2008; 454:126-130.
Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L, Wang L. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 2013; 14:319.

Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Gao X, Liu Z, Hou J, Huang J, Sun Y. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 2013; 49:2949-2959.

Gong C, Maquat LE. IncRNAs transactivate STA1-mediated mRNA decay by duplexing with 3’ UTRs via Alu elements. Nature 2011; 470:284-288.

Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, Willard HF. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature 1991; 349:38-44.

Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature 1991; 351:153-155.

Novikova IV, Hennelly SP, Tung CS, Sanbonmatsu KY. Rise of the RNA machines: exploring the structure of long non-coding RNAs. J Mol Biol 2013; 425:3731-3746.

Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009; 10:155-159.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Shhandier O, Chinappi M, Tramontano A, Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147:358-369.

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 2012; 9:703-719.

Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23:1494-1504.

Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 2012; 40:6391-6400.

Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81:145-166.

Cesana M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25:1915-1927.

Nana-Sinkam SP, Croce CM. Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol Oncol 2011; 5:483-491.

Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo YY. lncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 2013; 41:4976-4987.

Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-1076.

Gibb EA, Enfield KS, Stewart GL, Lonergan KM, Char I, Ng RT, Zhang L, MacAulay CE, Rosin MP, Lam WL. Long non-coding RNAs are expressed in oral mucosa and altered in oral premalignant lesions. Oral Oncol 2011; 47:1055-1061.

Pibouin L, Villaudy J, Ferbus D, Muleris M, Prosperi MT, Remvikos Y, Goubin G. Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet 2002; 133:55-60.

Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-693.

Wu SC, Kallin EM, Zhang Y. Role of H3K27 methylation in the regulation of IncRNA expression. Cell Res 2010; 20:1109-1116.

Zhang K, Sun X, Zhou X, Han L, Chen L, Shi Z, Zhang A, Ye M, Wang Q, Liu C, Wei J, Ren Y, Yang J, et al. Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget 2015; 6:537-546. doi: 10.18632/oncotarget.2681.

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71:6320-6326.

Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, Al-Sharef W, De-Groot N, Hochberg A. Possible physiological role of H19 RNA. Mol Carcinog 2002; 35:63-74.

Thorvaldsen JL, Duran KL, Bartolomei MS. Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev 1998; 12:3693-3702.

Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, Tsao MS, Penn LZ. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 2010; 70:12417-12422.

Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, Riccio A, Colnot S, Godard C, Terris B, Jammes H, Dandolo L. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA 2008; 105:12417-12422.

Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, Huo XS, Xu D, Bi HS, Wang F, Sun SH. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis...
suppression in hepatocellular carcinoma. Carcinogenesis 2013; 34:577-586.

42 Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab 2005; 90:2179-2186.

43 Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M. Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res 2005; 65:26-33.

44 Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 2012; 48:R45-53.

45 Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman V, Xega K, Contino G, et al. RNA sequencing of pancreatic tumors implicates WNT signalling in colorectal cancer. Oncotarget 2015; 6:22513-22525. doi: 10.18632/oncotarget.3909.

46 Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, Waye MM. The IncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal carcinoma. Oncotarget 2015; 6:22513-22525. doi: 10.18632/oncotarget.4154.

47 Pantoja C, de Los Rios L, Matheu A, Antequera F, Serrano M. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lncRNA implicated in disease progression. Nat Biotechnol 2011; 29:742-749.

48 Zhao J, Dahle D, Zhou Y, Zhang X, Batista DL, Gejman V, Xega K, Contino G, et al. RNA sequencing of pancreatic tumors implicates WNT signalling in colorectal cancer. Oncotarget 2015; 6:22513-22525. doi: 10.18632/oncotarget.3909.

49 Panzitt K, Tschemnatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2009; 132:330-342.

50 Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Davis M, Zhao J, Dahle D, Zhou Y, Zhang X, et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol 2013; 30:588.

51 Panzitt K, Tschemnatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2009; 132:330-342.

52 Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, Reik W. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 2012; 14:659-665.

53 Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 2007; 13:313-316.

54 Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, Kwok TT. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010; 31:350-358.

55 Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 2007; 13:313-316.

56 Poliseno L, Haimovic A, Christos PJ, de Miera EC, VYS, Shapiro R, Pavlick A, Berman RS, Darvishian F, Osman I. Deletion of PTENP1 pseudogene in human melanoma. J Invest Dermatol 2011; 131:2497-2500.
metastasis. Nature 2012; 487:510-513.

66 Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klubanski A. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 2010; 151:939-947.

67 Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22:8031-8041.

68 Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26:851-858.

69 Xu C, Yang M, Tian J, Wang X, Li Z. MALAT-1: a long non-coding RNA and its important 3’ end functional motif in colorectal cancer metastasis. Int J Oncol 2011; 39:169-175.

70 Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, Blencowe BJ, Prasanth SG, Prasanth KV. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39:925-938.

71 Koshimizu TA, Fujiwara Y, Sakai N, Shibata K, Tsuchiya H. Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line. Life Sci 2010; 86:455-460.

72 Hung T, Chang HY. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol 2010; 7:582-585.

73 Sanchez-Elsner T, Gou D, Kremmer E, Sauer F. Noncoding RNAs of trithorax response elements recruit Drosophila Ash1 to Ultrabithorax. Science 2006; 311:1118-1123.

74 Wutz A. Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation. Nat Rev Genet 2011; 12:542-553.

75 Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22:8031-8041.

76 Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26:851-858.

77 Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics 2012; 28:2062-2063.

78 Paraskevopoulou MD, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas TM, Hatzigeorgiou AG. DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res 2013; 41:D239-245.

79 Yang JH, Li JH, Jiang S, Zhou H, Qu LH. ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data. Nucleic Acids Res 2013; 41:D177-187.

80 Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. The Long Intergenic Noncoding RNA URF1, a Target of MicroRNA 34a, Interacts With the mRNA Stabilizing Protein HuR to Increase Levels of beta-Catenin in HCC Cells. Gastroenterology 2015; 148:415-426.e18.

81 Guttmann M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011; 477:295-300.

82 Hu Y, Chen JY, Yu CY, Xu J, Wang J, Qian J, Zhang X, Fang JY. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget 2014; 5:2230-2242. doi: 10.18632/oncotarget.1895.

83 Gamal SM, Pedersen SK, Brown HO, T, Kassir Z, Moynihan AT, Vizgoft EK, Dunne R, Pimlott L, Young GP, Lapointe LC, Molloy PL. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene with Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer 2011; 2:829-840. doi: 10.1177/1947601911431081.

84 Svoboda M, Slyssova J, Schneiderova M, Makovicky P, Bielik L, Levy M, Lipska L, Hemmelova B, Kala Z, Protivankova M, Vycital O, Liska V, Schwarzova L, et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 2014; 35:1510-1515.

85 Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I, Gure AO, Stojadinovic A, Pan H, Tsivin V, Nissan A, Yavin E. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Lett 2014; 352:90-96.

86 He X, Tan X, Wang X, Jin H, Liu L, Ma L, Yu H, Fan Z. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumour Biol 2014; 35:12181-12188.

87 Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L, Yin R. CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol 2014; 35:5375-5380.

88 Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, Qian J, Liu N, You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. PLOS ONE 2014; 9:e86295.

89 Wu ZH, Wang XL, Tang HM, Jiang T, Chen J, Lu S, Qiu GQ, Peng ZH, Yan DW. Long non-coding RNA HOTAIR
is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer. Oncol Rep 2014; 32:395-402.

90 Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, Miyano S, Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71:6320-6326.

91 Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol 2012; 48:R45-53.

92 Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 2014; 281:1750-1758.

93 Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 2012; 41:276-284.

94 Yochum GS, Cleland R, McWeeney S, Goodman RH. An antisense transcript induced by Wnt/beta-catenin signaling decreases E2F4. J Biol Chem 2007; 282:871-878.

95 Ellis BC, Graham LD, Molloy PL. CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta 2014; 1843:372-386.

96 Ellis BC, Molloy PL, Graham LD. CRNDE: A Long Non-Coding RNA Involved in Cancer, Neurobiology, and Development. Front Genet 2012; 3:270.

97 Zheng J, Li XD, Wang P, Liu XB, Xue YX, Hu Y, Li Z, Li ZQ, Wang ZH, Liu YH. CRNDE affects the malignant biological characteristics of human glioma stem cells by negatively regulating miR-186. Oncotarget 2015; 6: 25339-25355. doi: 10.18632/oncotarget.4509.